Response to Comments: Trigger Point Injections (TPI)

This response-to-comments article summarizes and cites recent literature on trigger point injections and related interfascial/injection techniques for conditions such as myofascial pain syndrome, chronic non-malignant musculoskeletal pain, and cervicogenic headache. The document does not itself establish or modify explicit coverage indications, limitations, documentation requirements, or frequency limits—those remain in the primary Local Coverage Determination (LCD) or National Coverage Determination (NCD) and require review for final coverage rules.

"Trigger point injections (TPI) are discussed in the context of treating myofascial pain syndrome (MPS) in multiple cited clinical trials and reviews, suggesting MPS as an intended clinical context ..."

Sign up to see full coverage criteria, indications, and limitations.